A further combination approach involving PD-1 mAb and luteolin resulted in improved survival rates, decreased tumor volume and size, diminished lung lesions, increased number of CD8+ T cells, and enhanced activation phenotypes [227]. The gene discussed is PDCD1; the disease is neoplasm.